Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0600139 (Prostate Cancer)
 4,540 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

40 patients with prostatic carcinoma were treated with parenteral and/or oral Estracyt (estramustine phosphate) until 55 months. Metastases were present in 37 patients (stage D). 35 of the 40 patients developed metastases in spite of estrogen therapy and/or orchidectomy. Diminution of metastasic bone pain as well as improvement of hydroureteronephrosis was frequently observed. Paraplegia secondary to metastatic disease improved in 1 case for 6 months. Side effects were relatively rare and were mainly gastrointestinal. A possible hepatotoxic action of the compound has been pointed out previously. On the basis of our studies Estracyt is recommended in the treatment of primary estrogen resistent prostatic carcinoma and in metastatic carcinoma of the prostate not responding to conventional antiandrogenic therapy anymore.
 ...
PMID:[Treatment of advanced carcinoma of the prostate with Estracyt (author's transl)]. 82 40

We describe a patient with metastatic carcinoma of the prostate associated with paraplegia. The patient also had Paget's disease of bone elsewhere. Because the neurological lesion was thought to be due to Paget's disease, the patient was treated with inhibitors of bone resorption. Treatment rapidly induced clinical remission and inhibition of bone resorption, and withdrawal was associated with relapse. This suggests that such agents may be of value in the treatment of bone disease of prostatic carcinoma.
 ...
PMID:Carcinoma of the prostate: remission of paraparesis with inhibitors of bone resorption. 316 14

We describe a patient in whom symmetrical acrokeratosis appeared 6 years before the diagnosis of metastatic carcinoma of the prostate causing paraplegia. The paraneoplastic dermatosis and paraplegia regressed following treatment with stilboestrol and topical applications of 2% salicylic acid in vaseline. To our knowledge, Bazex acrokeratosis has not been reported previously in association with carcinoma of the prostate.
 ...
PMID:Bazex paraneoplastic acrokeratosis in prostate carcinoma. 368 83

Metastatic carcinoma of the prostate is a common cause of spinal cord compression. In this review of 37 men who underwent laminectomy for this condition this was the first presentation of previously undiagnosed cancer in 11 (29%). One year after decompression 17 (50%) were alive. Twenty patients (59%) could walk after laminectomy. All but 8 were relieved of pain and bladder function was improved in 13 (38%). Those ambulant before laminectomy (7) and those with occult prostate cancer did particularly well. Poor results were associated with a rapid onset of paraparesis and pre-operative progression to paraplegia. A delay in diagnosis was detrimental to outcome. A high index of suspicion in patients with carcinoma of the prostate is essential so that early diagnosis can be made before paraplegia is established. Carcinoma of the prostate must always be excluded in men with cord compression of unknown aetiology.
 ...
PMID:Cord compression and carcinoma of the prostate: is laminectomy justified? 408 36

When paraplegia occurs as a result of malignant disease, it generally means that the patient's survival is limited to a few months. The exceptions to this rule include patients with paraplegia or quadraplegia as a result of metastases from carcinoma of the prostate. This study concerns 24 men with paraplegia, 20 of whom lived for over 5 years following the onset of paralysis, 18 being rehabilitated. The prostatic cause of paralysis may not be obvious at the first, and conventional X-rays of the spine may be negative. The serum acid phosphatase was raised in several cases, confirmation of the diagnosis could either be made by biopsy of the prostate gland or, if laminectomy is performed, by examining the tissue that compresses the spinal cord. Laminectomy is recommended only in patients with rapidly advancing neurological signs. The treatment of choice is orchidectomy rather than hormonal treatment in the elderly age group, as oestrogens cause cardio-vascular complications.
 ...
PMID:Paraplegia and prostatic cancer. 662 68

To test the hypothesis that carcinoma of the prostate (CAPR) is uncommon among patients previously paralyzed due to myelopathy, the prevalence of CAPR in patients with high grade (severe) paralysis was compared to that in patients with low grade paralysis. Sixty-six records of patients with CAPR following myelopathy were recalled from the Department of Veterans Affairs medical database for a seven-year period, 1986-1992. Thirty-four patients were unable to stand (high grade paralysis) and 32 patients could stand (low grade paralysis). The minimal, expected ratio of high to low grade paralysis is 2.3, based on general myelopathy populations, but the observed ratio was 1.1, p < 0.01. Patient age and racial distribution, duration and level of paralysis, stage and fraction of CAPR diagnosed incidentally were similar in the high and low paralysis groups. We conclude that severe paralysis due to myelopathy is underrepresented among myelopathy patients with CAPR and is therefore a relatively low risk factor for carcinoma of the prostate gland.
J Am Paraplegia Soc 1994 Jul
PMID:Low prevalence of prostatic cancer among myelopathy patients. 796 11

Metastatic spinal cord compression (MSCC) is a serious complication of metastatic prostate cancer (PCa). This study retrospectively evaluated patients who presented with paraplegia or quadriplegia because of MSCC of PCa. Of 847 patients with PCa who were treated between 1989 and 1998, 26 (3.1%) demonstrated paraplegia or quadriplegia because of MSCC. Characteristics, treatment efficacy, and prognosis of these patients were analyzed. In total, 15 cases became paraplegic despite androgen ablation therapy (Group I). Average time to paraplegia from initial hormonal treatment was 34 months. Out of nine cases who underwent radiation therapy (RT) to spinal lesions with/without chemotherapy, one patient became ambulatory. However, this patient subsequently had recurrent compression. Two cases had remission of paralysis. Two cases underwent laminectomy plus RT and in one case paralysis improved. MSCC was the first indication of PCa in 11 cases (Group II). Two cases underwent laminectomy plus hormone therapy and nine cases underwent hormone therapy alone. Four patients became ambulatory and two cases showed improved motor capacity. Average interval from paraplegia to death was 7.4 months in Group I and 27.1 months in Group II. However, there was no statistical difference in these two groups on disease-specific survival from the start of initial treatment. It is difficult to recover the ability to walk if paraplegia or quadriplegia occurs in PCa patients although decompression surgery plus hormone therapy seemed to impair the prognosis. Stage M1 patients with paraplegia had survival rates as good as stage M1 patients without paralysis. This should encourage an aggressive treatment approach. However, for patients with hormone-independent disease there seems to be no effective treatment and prognosis is poor.
Prostate Cancer Prostatic Dis 2003
PMID:Treatment and prognosis of patients with paraplegia or quadriplegia because of metastatic spinal cord compression in prostate cancer. 1280 78